Arcus Biosciences discontinues lung cancer study due to futility

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Arcus Biosciences discontinues lung cancer study due to futility
(NYSE: RCUS) Delayed: 23.80 +0.50 (2.15%)
Previous Close $23.30    52 Week High $ 
Open $23.50    52 Week Low $ 
Day High $24.11    P/E N/A 
Day Low $23.27    EPS $ 
Volume 1,447,474